Cerus Corp (CERS):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Cerus Corp (CERS) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C9865
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:43
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Cerus Corp (Cerus) is a biomedical products company that focuses in the field of blood transfusion safety. It develops and commercializes the INTERCEPT Blood System to enhance blood safety. INTERCEPT Blood System reduces the risk of transfusion-transmitted infections by inactivating a wide range of pathogens including viruses, bacteria and parasites present in donated blood. The product is for use with three blood components, platelets, plasma and red blood cells. Cerus is marketed and sold in several countries worldwide including the US, Belgium, Kuwait, France, Spain, Portugal, Switzerland, CIS countries and other countries. Cerus is headquartered in Concord, California, the US.

Cerus Corp (CERS) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Cerus Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Cerus Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Cerus Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Cerus Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Cerus Corp, Medical Devices Deals, 2012 to YTD 2018 9
Cerus Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Cerus Corp, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
Cerus Enters into Partnership with Biomedical Advanced Research and Development Authority 11
Cerus Enters Into Co-Development Agreement With Nipro 12
Cerus Enters Into Distribution Agreement With American Red Cross For Intercept Plasma 13
Cerus Enters Into Distribution Agreement With Blood Systems For Intercept Plasma 15
Cerus Enters Into Co-Development Agreement With New York Blood Center 17
Equity Offering 18
Cerus Raises USD57.5 Million in Public Offering of Shares 18
Cerus Plans to Raise USD70 Million in Public Offering of Shares 19
Cerus raises USD80.5 Million in Public offering of shares 20
Cerus Corp – Key Competitors 21
Cerus Corp – Key Employees 22
Cerus Corp – Locations And Subsidiaries 23
Head Office 23
Other Locations & Subsidiaries 23
Recent Developments 24
Financial Announcements 24
Nov 01, 2018: Cerus reports third quarter 2018 results 24
Aug 02, 2018: Cerus announces second quarter 2018 financial results 26
May 08, 2018: Cerus Reports First Quarter 2018 Results 28
Mar 08, 2018: Cerus Reports Fourth Quarter And Year End 2017 Financial Results 30
Jan 08, 2018: Cerus Announces Preliminary Product Revenue Results for Fourth Quarter and Full Year 2017 32
Nov 02, 2017: Cerus Corporation Reports Third Quarter 2017 Results 33
Aug 03, 2017: Cerus Reports Second Quarter 2017 Results 35
May 03, 2017: Cerus Reports First Quarter 2017 Results 37
Mar 07, 2017: Cerus Reports Fourth Quarter and Year End 2016 Results 38
Corporate Communications 40
Oct 09, 2018: Cerus appoints Eric Bjerkholt to board of directors 40
Product News 41
Jun 21, 2017: INTERCEPT Blood System Highlighted at the International Society of Blood Transfusion 41
Other Significant Developments 42
Jun 07, 2017: Cerus Provides Update on U.S. Platelet Additive Solution Supply 42
Appendix 43
Methodology 43
About GlobalData 43
Contact Us 43
Disclaimer 43

List of Tables
Cerus Corp, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Cerus Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Cerus Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Cerus Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Cerus Corp, Deals By Therapy Area, 2012 to YTD 2018 8
Cerus Corp, Medical Devices Deals, 2012 to YTD 2018 9
Cerus Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Cerus Enters into Partnership with Biomedical Advanced Research and Development Authority 11
Cerus Enters Into Co-Development Agreement With Nipro 12
Cerus Enters Into Distribution Agreement With American Red Cross For Intercept Plasma 13
Cerus Enters Into Distribution Agreement With Blood Systems For Intercept Plasma 15
Cerus Enters Into Co-Development Agreement With New York Blood Center 17
Cerus Raises USD57.5 Million in Public Offering of Shares 18
Cerus Plans to Raise USD70 Million in Public Offering of Shares 19
Cerus raises USD80.5 Million in Public offering of shares 20
Cerus Corp, Key Competitors 21
Cerus Corp, Key Employees 22
Cerus Corp, Subsidiaries 23

List of Figures
Cerus Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Cerus Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Cerus Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Cerus Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Cerus Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Cerus Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Cerus Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Cerus Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Cerus Corp, Medical Devices Deals, 2012 to YTD 2018 9

★海外企業調査レポート[Cerus Corp (CERS):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Republic Airline, Inc.:企業の戦略・SWOT・財務情報
    Republic Airline, Inc. - Strategy, SWOT and Corporate Finance Report Summary Republic Airline, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • CiCi Enterprises, LP:企業の戦略・SWOT・財務情報
    CiCi Enterprises, LP - Strategy, SWOT and Corporate Finance Report Summary CiCi Enterprises, LP - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Theralase Technologies Inc (TLT):企業の財務・戦略的SWOT分析
    Summary Theralase Technologies Inc (Theralase) is a clinical stage pharmaceutical company which specializes in design, development, and manufacturing of laser based technologies used in wide range of bio-destructive and bio-simulative clinical applications. The company is focused on the development …
  • Pieridae Energy Ltd (PEA):石油・ガス:M&Aディール及び事業提携情報
    Summary Pieridae Energy Ltd (Pieridae Energy), formerly Petrolia Inc, is an oil and gas company that develops, explores, and produces oil resources. The company’s projects comprise Haldimand project, Bourque project, Tar Point project, Corte-Real project, Anticosti project, Dalhousie project; Edgar, …
  • Kuros Biosciences AG (KURN):企業の製品パイプライン分析
    Summary Kuros Biosciences AG (Kuros Biosciences) is a developer of products for tissue repair and regeneration. It develops a family of bone healing products to address indications in trauma and spine called orthobiologics. It is focused on bone repair for trauma, specifically fracture repair, as we …
  • Orange and Rockland Utilities, Inc.:企業の戦略的SWOT分析
    Orange and Rockland Utilities, Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major …
  • JW Pharmaceutical Corp (001060):製薬・医療:M&Aディール及び事業提携情報
    Summary JW Pharmaceutical Corp (JW Pharmaceutical), a subsidiary of JW Holdings Corp is a provider of generic drugs. The company develops and markets analgesics, antipyretics and cold remedy, antidote agents, antimicrobials, anticancer agents, and others. It offers multivitamins and antianemic agent …
  • Tenet Healthcare Corp (THC):企業の財務・戦略的SWOT分析
    Tenet Healthcare Corp (THC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • NKT AS (NKT):企業の財務・戦略的SWOT分析
    NKT AS (NKT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the pote …
  • Electricidade de Mocambique EP-エネルギー分野:企業M&A・提携分析
    Summary Electricidade de Mocambique EP (EDM) is a state owned vertically integrated energy utility that generates, distributes, transmits, and commercializes electricity. The company produces electricity from hydro and thermal sources. It has interests in Lichinga, Cuamba, Corumana, Chicamba, and Ma …
  • Atomstroyexport:企業の戦略的SWOT分析
    Atomstroyexport - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servic …
  • Green Cross Cell Corp (031390):企業の財務・戦略的SWOT分析
    Green Cross Cell Corp (031390) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Tonix Pharmaceuticals Holding Corp (TNXP):企業の財務・戦略的SWOT分析
    Summary Tonix Pharmaceuticals Holding Corp (Tonix) is a developer of pharmaceutical products to address public health challenges. The company offers pharmaceutical products and treatments for disorders of the central nervous system including fibromyalgia, post traumatic stress disorder and episodic …
  • Far Eastone Telecommunications Co Ltd (4904):企業の財務・戦略的SWOT分析
    Far Eastone Telecommunications Co Ltd (4904) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key stren …
  • Kawasaki Kisen Kaisha, Ltd. (9107)-石油・ガス分野:企業M&A・提携分析
    Summary Kawasaki Kisen Kaisha, Ltd. (K Line) is a global logistics company. K Line’s business lines include land transportation, air transportation, marine transportation, and harbor transportation. It owns and operates dry bulk carriers, LNG carriers, tankers, car carriers and containerships. The c …
  • Asure Software, Inc. (ASUR):企業の財務・戦略的SWOT分析
    Asure Software, Inc. (ASUR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Genmab AS (GEN):製薬・医療:M&Aディール及び事業提携情報
    Summary Genmab A/S (Genmab) is a biotechnology company that develops differentiated human antibody therapeutics for the treatment of cancer. The company's marketed antibody, ofatumumab (Arzerra) and Daratumumab (Darzalex) are indicated for the treatment of chronic lymphocytic leukemia and multiple m …
  • Smith & Nephew plc:企業のM&A・事業提携・投資動向
    Smith & Nephew plc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Smith & Nephew plc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), d …
  • BioFire Diagnostics LLC:医療機器:M&Aディール及び事業提携情報
    Summary BioFire Diagnostics LLC (BioFire Diagnostics), formerly Idaho Technology Inc, a subsidiary of bioMerieux SA, is a molecular diagnostics company that offers molecular biology products. The company offers solutions for healthcare providers, labs and customers. It provides respiratory, meningit …
  • Berg LLC:医療機器:M&Aディール及び事業提携情報
    Summary Berg LLC (Berg) is a biopharmaceutical company that focus on therapeutic discovery using AI-based Interrogative biology platform. The company’s proprietary platform Interrogative Biology, combines patient biology and artificial intelligence-based analytics to understand predictive patterns o …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆